Cargando…
MAFLD: a multisystem disease
Nonalcoholic fatty liver disease (NAFLD), affecting about 25% of general population and more than 50% of dysmetabolic patients, is an emerging cause of chronic liver disease and its complications. Recently, an international consensus of experts proposed to rename this disease as ‘Metabolic dysfuncti...
Autores principales: | Pipitone, Rosaria Maria, Ciccioli, Carlo, Infantino, Giuseppe, La Mantia, Claudia, Parisi, Stefanie, Tulone, Adele, Pennisi, Grazia, Grimaudo, Stefania, Petta, Salvatore |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9885036/ https://www.ncbi.nlm.nih.gov/pubmed/36726391 http://dx.doi.org/10.1177/20420188221145549 |
Ejemplares similares
-
Emerging pharmacological treatment options for MAFLD
por: Rojas, Ángela, et al.
Publicado: (2022) -
Screening for MAFLD: who, when and how?
por: Pal, Shreya C., et al.
Publicado: (2023) -
Should we undertake surveillance for HCC in patients with MAFLD?
por: Norero, Blanca, et al.
Publicado: (2023) -
Non-pharmacological management options for MAFLD: a practical
guide
por: Stefano, José Tadeu, et al.
Publicado: (2023) -
The bidirectional impacts of alcohol consumption and MAFLD for progressive fatty liver disease
por: Kulkarni, Anand V., et al.
Publicado: (2023)